Marc Stegman, MD
Nephrology · Memphis, TNNPI 1023019825
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,400 of the $41,076 with a category attached, or 64.3%. Fresenius USA Marketing, Inc. accounts for 67.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $17,233 and has fallen 95.3% since, to $818 in 2024. Among nephrology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $118.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$28K
- AstraZeneca$5K
- Aurinia Pharma U.S., Inc.$4K
- Otsuka America Pharmaceutical, Inc.$1K
- Amgen$882
- Mallinckrodt Hospital Products Inc.$552
- plus $3K from 15 others
What the payments were for
- Speaking & faculty fees$26,40064%
- Travel & lodging$5,90414%
- Food & beverage$8,57521%
- Education$1970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 96 | $27,529 |
| AstraZeneca(2 entities) | 54 | $4,524 |
| Aurinia Pharma U.S., Inc. | 20 | $3,634 |
| Otsuka America Pharmaceutical, Inc. | 41 | $1,154 |
| Amgen(2 entities) | 26 | $882 |
| Mallinckrodt Hospital Products Inc. | 19 | $552 |
| Bayer | 14 | $507 |
| Travere Therapeutics, Inc. | 17 | $455 |
| Vifor Pharma, Inc. | 18 | $366 |
| GSK | 11 | $360 |
| Ardelyx, Inc. | 7 | $342 |
| Calliditas Therapeutics US Inc. | 3 | $152 |
| Mallinckrodt Enterprises LLC | 7 | $132 |
| Esperion Therapeutics, Inc. | 1 | $119 |
| Johnson & Johnson | 1 | $119 |
| Novartis | 3 | $89 |
| OPKO Pharmaceuticals, LLC | 2 | $42 |
| La Jolla Pharmaceutical Company | 2 | $42 |
| Sanofi | 2 | $40 |
| Akebia Therapeutics Inc | 1 | $23 |
| Amicus Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,076 in reported general payments places this provider in the 90th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FabrazymeAgalsidase Beta | 24 | $730,331 |
| VelphoroSucroferric Oxyhydroxide | 60 | $159,965 |
| XphozahTenapanor Hcl | 18 | $55,649 |
| FarxigaDapagliflozin Propanediol | 24 | $21,616 |
| Sevelamer Carbonate | 25 | $6,436 |
| Tacrolimus | 11 | $4,506 |
| Hydralazine Hcl | 29 | $575 |
| Labetalol Hcl | 11 | $453 |
| Atorvastatin Calcium | 14 | $216 |
| Calcitriol | 11 | $201 |
| Prednisone | 25 | $192 |
| Doxazosin Mesylate | 11 | $180 |
| Allopurinol | 16 | $173 |
| Amlodipine Besylate | 59 | $170 |
| Pantoprazole Sodium | 12 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiFabrazyme | $40 | $730,33124 claims |
| Fresenius USA Marketing, Inc.Velphoro | $27,529 | $159,96560 claims |
| AstraZenecaFarxiga | $4,524 | $21,61624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Memphis
- Omar HamzeMemphis$90K
- Omar DavisMemphis$70K
- Natarsha GrantMemphis$53K
- Robert CanadaMemphis$20K
- Minesh PathakMemphis$14K
- Miklos MolnarMemphis$12K
- Wael HusseinMemphis$10K
- Sanjeev MittalMemphis$9K
- Vasanthi BalaramanMemphis$8K
- Mark Abi NaderMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.